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Background: A dietary supplement containing a blend of 170 mg of N-oleyl-phosphatidylethanolamine (NOPE)
and 100 mg of epigallocatechin-3-gallate (EGCG) has been shown to improve compliance to low caloric diets.
Considering the cost of dietary ingredients, many manufacturers attempt to determine the lowest efficacious dose.
Thus, the purpose of this study was to evaluate the efficacy of 8-weeks of supplementation with a daily intake of
120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise on
dietary compliance in healthy, overweight adults. An additional purpose was to examine the effect of this
supplement/diet/exercise paradigm on changes in body composition, sensation of appetite, mood and severity of
binge eating.
Methods: Fifty healthy, overweight (BMI > 25 m·kg2) men (15) and women (35) (SUP; n = 25; 32.7 ± 13.75 y;
BMI = 33.4 ± 6.2; PLA; n = 25, 34.3 ± 12.7 years; BMI = 33.2 ± 6.8) were recruited for a double-blind, placebo controlled
study. Each volunteer was randomly assigned to either the supplement (SUP; n = 25) or placebo group (PLA;
n = 25). Based upon a self-reported 3-day dietary recall all volunteers were recommended a 500 kcal or 30%
(maximum of 1000 kcal) reduction in caloric intake. Volunteers were also encouraged to exercise 30 minutes per
day, three times per week.
Results: Subjects in SUP were significantly more compliant (x2 = 3.86, p = 0.049) in maintaining a low caloric diet at
week 4, but this was not able to be maintained through the 8-week study. In addition, a significant difference in
mood, feelings of fatigue and confusion were noted between the groups at week 4, but again not maintained by
week 8 where only feelings of tension were improved. No differences between groups (p > 0.05) were observed for
body mass, body composition, feelings of hunger, and binge eating after eight weeks.
Conclusion: Supplementing with a combination of 120 mg of NOPE and 105 mg of EGCG does appear to enhance
compliance to a low caloric diet and improve mood for 4 –weeks, but loses its effectiveness by week 8.
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Excess body weight is a major health problem in the
United States. More than 60% of adult Americans are
classified as being overweight [1] and approximately 34%
as obese [2]. Excess body fat increases the risk for
several debilitating and potentially fatal diseases [3-7].
Research indicates that body mass index, waist circum-
ference, and body fat percentages can be significantly
reduced through a combination of diet and exercise, in
comparison to diet alone [8,9]. However, a major deter-
minant for success during a weight loss regimen is an
individual’s ability to adhere to a low calorie diet for an
extended duration [10,11]. Although caloric restriction is
an effective method of losing body weight and body fat,
it becomes more challenging if adherence to the diet
cannot be maintained [11]. In response to this need the
pharmaceutical industry developed a number of pre-
scription medications to enhance the success of weight
loss programs. Although there has been varying degrees
of success [12], a high incidence of adverse events has
shifted research to the development of non-prescription
interventions [13-15]. Non-prescription weight loss sup-
plements focus on several different mechanisms of ac-
tion including enhancing satiety, thermo genesis, and
the inhibition of enzymes that metabolize both carbohy-
drates and fats [16]. However, the efficacy and safety of
these interventions has not been fully elucidated.
N-oleoyl-phophatidyl-ethanolamine (NOPE) and
epigallocatechin gallate (EGCG) are naturally occurring
nutritional ingredients, whose biological properties may
enhance compliance to a reduced calorie diet [17-28].
NOPE, a naturally occurring phospholipid found in
animal and vegetable foods, is hydrolyzed into N-oleyl-
ethanolamide (NOE) and phosphatidic acid when con-
sumed [17]. Its proposed mechanism of action is related
to NOE’s role in inhibiting the effect of anandamide
(N-arachidonyl-ethanolamine), an agonist of both per-
ipheral and central cannabinoid type 1 receptors (CB1)
whose activation leads to an increase in appetite and,
consequently, an intake of food [18]. In rats, an intra-
peritoneal injection of NOE has been shown to promote
an anorexic effect through the activation of several intes-
tinal receptors, which signal the brain center to reduce
food intake [19,20]. EGCG, from standardized green tea
extract, has been shown to stimulate weight [21,22] and
fat loss [22,23] by inhibiting enzymes that contribute to
the degradation of catecholamines [24,25], which stimu-
late lipolysis. In mice fed a high-fat diet, EGCG supple-
mentation has been shown to attenuate gains in body
mass, total body fat, and visceral fat [26]. Others have
suggested that NOPE and EGCG by themselves may not
be effective for weight loss [27,28], However, other
investigators have demonstrated that a combination of
these compounds may result in improved absorption ofEGCG and prevent the rapid breakdown of NOPE, im-
proving its availability [28].
A recent study in humans reported that a combination
of NOPE (170 mg·day-1) and EGCG (100 mg·day-1)
resulted in greater low calorie dietary compliance,
improved mood and satiation, as well as decreases in de-
pressive symptoms compared to a placebo [17]. How-
ever, weight loss was similar between groups, suggesting
body weight reductions were not directly related to the
dietary supplement. Thus, the purpose of this study was
to determine if a proprietary blend of NOPE and EGCG,
using lower concentrations of NOPE than previously
reported, in conjunction with regular exercise, could im-
prove dietary compliance to a low caloric diet and result




Fifty healthy adults (35 female, 15 male) volunteered to
participate in an 8-week randomized, double-blind investi-
gation. Following an explanation of all procedures, risks,
and benefits associated with the experimental protocol,
each volunteer gave his or her written informed consent
to participate in this study. The research protocol was
approved by the Institutional Review Board at the Univer-
sity of Central Florida. Inclusion criteria required partici-
pants to be between 18 – 59 years of age, with a body
mass index (BMI) greater than 25 but less than 40, and
their daily energy intake to be at, or above their calculated
dietary fuel requirement. Participants were randomly
assigned to one of two groups. One group was provided
the supplement (SUP; n = 25; 17 females, 8 males; 32.7 ±
13.7 years; 93.3 ± 19.5 kg; BMI = 33.4 ± 6.2; 43.2 ± 7.2%
Body Fat) containing 120 mg NOPE and 105 mg of
EGCG, and the second group was provided a placebo
(PLA; n = 25, 18 females, 7 males; 34.3 ± 12.7 years; 92.8 ±
18.6 kg; BMI = 33.26 ± 6.8; 44.0 ± 6.8% Body Fat) contain-
ing an equivalent amount of rice flour.
Study design
The study protocol was 8-weeks in duration and
included a total of 6 visits with the investigators that
included an initial familiarization visit. If enrolled, the
subject returned to the Human Performance Laboratory
for baseline measures (WK0) and then every two weeks
for follow-up assessments (WK2, WK4, Wk6, and WK8,
respectively). During the initial familiarization session,
an explanation of study procedures associated with the
experimental protocol was provided to potential sub-
jects. Upon giving his or her written informed consent
to participate in the study, the subject was asked to
complete a medical history questionnaire. In addition,
the subject’s BMI was calculated and then checked to
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criteria. If the subject was enrolled into the study, they
were then instructed to complete a 3-day dietary recall,
consisting of two weekdays and one weekend day, to de-
termine daily caloric intake. The 3-day dietary recall was
returned for analysis prior to baseline measurements, to
determine if caloric intake met the study’s inclusion cri-
teria. During each subsequent laboratory visit anthropo-
metric measures and study questionnaires were
completed. The study protocol is described in Figure 1.
During the study subjects were recommended to main-
tain a regular exercise schedule that included at least
3 days per week, for 30 minutes per day at an intensity
that that would elicit between 60 – 75% of the subject’s
maximum heart rate. Volunteers were instructed to record
their daily activity and provide these records to the investi-
gators at each visit.Dietary analysis
The 3-day dietary recall was analyzed using the Food
Works 13 Nutritional Assessment Software (The
Nutrition Company, Long Valley, NJ, USA) and average
caloric intake was determined. Total Energy Expenditure
(TEE) was determined by a formula previously published
[29] and used to exclude individuals who did not meet
the study’s inclusion criteria. Subject’s TEE was
determined by age, height, weight, and reported physical
activity. If the subject’s dietary recall indicated that their
daily caloric intake was at or above the TEE, they were
then recommended a diet that was 30% or 500 kcal per
day (whichever was greater) less than what they had
been consuming. However, the maximum restriction did
not exceed 1000 kcal per day. The same investigator
provided dietary recommendations for each subject.
Compliance was measured as the ability to maintain the




















Figure 1 Flowchart of study design.8-week investigation. Caloric intake was reevaluated at
WK4 and WK8.Anthropometric measurements
Anthropometric measurements for all participants were
conducted in the following sequence: height (WK0 only)
and body mass, body mass index (BMI), waist circumfer-
ence, and Dual Energy X-Ray Absorptiometry (DEXA)
measurements. Body mass (measured to the nearest
0.1 kg) and height (measured to the nearest 0.01 m)
were determined using a Health-o-meter Professional
(Patient Weighing Scale, Model 500 KL, Pelstar, Alsip,
IL, USA). Measurements were performed with the parti-
cipants standing barefoot, with feet together, in their
normal daily attire. Body mass index (BMI) was
calculated as measured weight divided by the square of
measured height. Waist circumference was measured
using techniques previously described [30] by the same
investigator for each subject.
Body composition was determined using whole
body-dual energy x-ray absorptiometry (DEXA) scans
(Prodigy™; Lunar Corporation, Madison, WI). Total
body estimates of percent fat, fat and non-bone lean tis-
sue was determined using company’s recommended pro-
cedures and supplied algorithms. Quality assurance was
assessed by daily calibrations and was performed prior
to all scans using a calibration block provided by the
manufacturer.
Abdominal fat was determined as previously described
[31]. Briefly, a quadrilateral box was manually drawn
around the L1-L4 region of interest (abdomen) bounded
inferiorly by the horizontal line identifying the L4/L5
vertebral space and superiorly by the horizontal line
identifying the T12/L1 vertebral space. Scans were dis-
played with an adjustment of the gray scale, so that all
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Q = Questionnaires (Binge Eating Scale, Profile 
of Mood States, and Hunger and Satiety Scale) 
DX = DEXA and waist circumference 
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The Hunger and Satiety Scale (HSS) [32], Profile of
Mood States (POMS) [33], and Binge Eating Scale (BES)
[34] were administered during each visit beginning
WK0. The HSS was assessed numerically, using a scor-
ing system graded from 0, to represent ravenous hunger,
to plus 10, which represents feeling stuffed or overfull.
Volunteers were shown a scale with ten gradations and
asked to indicate how they felt in respect to hunger or
satiety by circling the appropriate place along the scale.
The scale also consisted of phrases describing the vari-
ous degrees of hunger or satiety, but volunteers were
free to choose any point along the scale [32]. The POMS
consists of 58 words or phrases in a Likert format ques-
tionnaire which provides measures of specific mood
states. It provides measures of tension, depression, anger,
vigor, fatigue and confusion. A total mood score is com-
puted by subtracting vigor from the sum of the five
other negative measures and adding 100 to avoid a nega-
tive result [33]. The BES, which has been shown to be a
valid and reliable measure of classifying binge eaters,
included sixteen items measuring the severity of binge
eating. It examines both behavioral manifestations (eat-
ing large amounts of foods) and feeling/cognition during
a binge episode (loss of control, guilt, and fear of being
unable to stop eating). Participants scoring 17 or lower
on the BES were classified as non-binge eaters, those
with a score of 18 – 26 as moderate binge eaters, and
those scoring 27 or higher as severe binge eaters [34].
All questionnaires were performed under controlled
conditions (a quiet room alone with the investigator).
During all test administrations participants were asked
to describe their feelings upon how they were feeling at
the moment.Supplement
The supplement, marketed as PhosphoLean™ (Chemi
Nutra, White Bear Lake, MN), contained a proprietary
blend of NOPE, a naturally occurring phospholipid
found in soy, and EGCG, from standardized green tea
extract. Each capsule contained 40 mg of NOPE, 35 mg
of EGCG and 25 mg of mixed phospholipids. The pla-
cebo contained an equal amount of rice flour. Partici-
pants were instructed to ingest 300 mg per day (three
capsules, 100 mg per capsule) of SUP or PLA (100 mg
rice flour per capsule); one capsule was consumed
60 minutes prior to lunch and two capsules 60 minutes
prior to dinner.Statistical analysis
The efficacy of the supplement was determined by calcu-
lating the change (Δ score) from WK0 to each measuring
point (WK2, WK4, WK6 and WK8). Due to participantdrop out or removal, the number of participants per visit
was reduced. To account for the different sample sizes at
each time point independent t-tests using the Bonferroni
method to correct for multiple assessments was employed
to compare group differences. Chi-square analysis was
used to analyze compliance at WK4 and WK8. A criterion
alpha level of p ≤ 0.05 was used to determine statistical
significance prior to Bonferroni correction.
Results
Thirty-two (SUP: 11 females, 5 males; PLA: 12 females, 4
males) of the original fifty volunteers completed the study.
Seven participants (SUP = 4, PLA = 3) dropped out by
WK2, Four additional participants (SUP = 2, PLA = 2)
dropped out after WK4, and five participants (SUP = 3,
PLA = 2) were deemed to be non-adherent. Non-
adherence was defined as participants who did not take a
minimum of 70% of the product or who did not complete
their final measurements. Their data were not included in
any of the analyses. Of the remaining two participants,
one in the SUP group withdrew from the study (prior to
WK2) when she was diagnosed with hypothyroidism,
which was not related to the supplement. The other sub-
ject, in the placebo group, experienced blurry vision, head-
ache, increased appetite, shakiness, and disrupted
alertness prior to WK2. Analysis of dietary recalls indi-
cated greater compliance (x2 = 3.86, p = 0.049) to the low
caloric diet in SUP (57.14%) compared to PLA (42.86%) at
WK4. However, no differences (x2 = 0.000, p = 1.000) in
dietary compliance were noted between the groups by
WK8. When comparing caloric intake between groups, no
difference from the change from WK0 were seen between
SUP (-889 ± 662 kcal and -911 ± 871 kcal) and PLA (-619 ±
1127 kcal and -718 ± 1337 kcal) at WK4 and WK8,
respectively.
Analysis of the participants self-reported exercise habit
revealed no significant differences (p = 0.577) in weekly
training frequency between PLA (p = 0.577; 2.7 ± 1.0 days
per week) and SUP (3.0 ± 1.6 days per week) or in minutes
per workout (p = 0.884; 55.6 ± 25.5 min versus 54.3 ± 15.5,
respectively). No significant differences were seen between
the groups in changes of body mass at any time point (see
Figure 2). Similarly, no significant differences were noted
in the change in % body fat (-0.4 ± 2.0% versus -0.1 ±
2.8%), lean body mass (-0.4 ± 1.6 kg versus -0.2 ± 1.6 kg),
waist circumference (-3.7 ± 1.6 cm versus -0.3 ± 7.8 cm)
and central adiposity (-0.3 ± 1.4 kg versus -0.3 ± 0.8 kg)
between PLA and SUP, respectively.
Changes from WK0 in HES and BES scores are shown
in Table 1. No significant differences in the Δ scores be-
tween the groups were noted at any time point. The
total mood score from the POMS assessment is depicted
in Figure 3. A significant difference between the groups
was seen at WK4. Participants ingesting the supplement
Figure 2 Changes from baseline in Body Mass.
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mood (a favorable response) than PLA. Similar patterns
were also noted for fatigue (p = 0.012) and confusion
(0.009) at WK4 (see Table 1). The only other significant
difference noted was observed at WK8, where changes
in tension was significantly (p = 0.002) different between
the groups.
Discussion
The results of this study suggest that a daily intake of
120 mg NOPE and 105 mg of EGCG for 4-weeks, can en-
hance compliance to a low caloric diet, total mood score,
feelings of fatigue, and confusion, but does not alter body
mass or body fat to any greater magnitude than placebo.Table 1 Changes from WK0 in hunger and satiety, binge eatin
WK2
Hunger and Satiety Scale PLA 0.21 ± 2.97
SUP 0.58 ± 1.39
Binge Eating Scale PLA -4.74 ± 3.75
SUP -5.74 ± 6.88
Profile of mo
Tension PLA 1.79 ± 5.90
SUP -0.37 ± 3.40
Depression PLA 2.84 ± 8.17
SUP -1.37 ± 2.34
Anger PLA 2.42 ± 3.88
SUP -0.53 ± 3.36
Vigor PLA 1.79 ± 16.31
SUP 3.47 ± 12.75
Fatigue PLA -0.47 ± 8.58
SUP -4.84 ± 11.35
Confusion PLA 3.37 ± 8.22
SUP -1.58 ± 5.27
* = significant difference between groups.However, these benefits were not maintained by week 8 of
the study, where only feelings of tension were reduced in
comparison to placebo. These findings contrast with Ron-
danelli et al., [17] in which sustained compliance and
improvements in feelings of satiety, and severity of binge
eating were observed for 8-weeks of study duration.
It is possible that the method used to determine dietary
compliance may have contributed to the differences be-
tween the studies. In the present investigation, compliance
was defined as the ability to maintain the recommended
low caloric diet. Rondonelli and colleagues defined com-
pliance in terms of drop-out rate [17]. This may not en-
tirely capture compliance, as approximately 72% of the
participants, who did not drop out of the present study,g and profile of mood states questionnaires
WK4 WK6 WK8
0.06 ± 2.28 0.46 ± 1.66 0.06 ± 1.39
0.27 ± 2.15 0.62 ± 1.71 0.31 ± 1.40
-6.53 ± 4.87 -8.00 ± 3.65 -7.06 ± 4.99
-5.71 ± 6.68 -5.67 ± 5.79 -6.53 ± 7.15
od states
1.35 ± 3.97 2.62 ± 7.70 0 ± 2.47
-2.07 ± 4.08 -2.25 ± 4.92 -3.20 ± 2.76*
0.88 ± 3.35 3.23 ± 11.58 0.59 ± 4.30
-1.86 ± 2.93 -1.17 ± 3.10 -1.07 ± 3.45
0.82 ± 1.94 2.38 ± 5.38 0.41 ± 1.33
-1.21 ± 2.39 -0.58 ± 3.40 -0.40 ± 3.25
5.47 ± 17.85 -0.38 ± 15.88 2.59 ± 14.62
8.21 ± 11.37 4.17 ± 8.48 7.80 ± 9.79
0.35 ± 4.40 2.85 ± 10.64 -3.65 ± 6.26
-5.64 ± 7.90* -3.58 ± 5.43 -5.27 ± 6.30
1.06 ± 5.03 3.69 ± 10.73 -1.12 ± 5.17

























Figure 3 Changes in total mood score. * = Significant difference (p = 0.006) between groups.
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more time points. This is supported by research investi-
gating the psychological biases in self-reporting dietary
habits in studies of caloric restraint [35,36]. Although a
participant may appear to be following the experimental
protocol by not withdrawing, many may seek either to
provide the results that researchers expect (compliance)
or to make their actions appear socially desirable [35,36].
Considering the lower daily caloric intakes of both groups,
calculated from self-reported dietary recalls, greater
reductions in body mass should have been observed. Re-
gardless, differences in compliance through WK4 between
the groups is likely attributable to the daily ingestion of
NOPE. However, the 50 mg per day lower dose used in
this study compared to previous research [17], may have
resulted in some degree of habituation following 4-weeks
of supplementation, as previous investigations have noted
dose-dependency [19,37].
It has been suggested that NOPE may curb appetite by
slowing down gastric emptying [38] and intestinal motil-
ity [39]. While the present study did not measure gastric
emptying and intestinal mobility directly, the lack of sig-
nificant differences in caloric intake or feelings of satiety
observed may reflect no differences in gastric emptying
and intestinal mobility. Although both groups experi-
enced reductions in caloric intake, possible differences
may have been confounded by the participants’ physical
activity habits. During lower intensity exercise (< 70%
VO2max), caloric intake may increase due to stimulated
gastric emptying [40,41], while more strenuous exercise
may delay gastric emptying [41], thus decreasing appe-
tite. Considering that exercise patterns were similar be-
tween the groups, it is possible that the potential
influence of NOPE on appetite [38,39] likely enhanced
dietary compliance through WK4.The NOPE and EGCG combination has also been
reported to reduce the severity of binge eating to a sig-
nificantly greater degree than placebo [17]. While the
present investigation noted decreases in BES scores for
both groups, no significant differences were observed at
any time point. However, baseline measurement scores
suggest that neither group could be defined as binge
eaters [34], which may imply that this proprietary sup-
plement blend may be more effective in binge eaters. It
is likely that reductions in BES scores in both groups
may have also been the result of the combined diet and
exercise program, as several studies have shown that a
combination of diet and exercise may prevent the onset
of binge eating in non-binge eaters [42,43].
The present investigation does support previous findings
that the NOPE-EGCG blend can significantly enhance
mood [17]. Oral supplementation of EGCG has been sug-
gested to impact central nervous system function in the
brain [44-46] by affecting γ-aminobutyric acid receptor
binding sites (GABAA) [47]. Since γ-Aminobutyric acid is
the principal inhibitory neurotransmitter receptor system
in the brain that regulates anxiety, EGCG ingestion may
reduce anxiety. EGCG was been shown to reduce anxiety
in mice [48,49], while regular green tea consumption low-
ers post-stress cortisol levels and increases subjective re-
laxation in humans [50]. Our findings show that mood,
feelings of depression and confusion are all improved after
four weeks of supplementation, with improvements in
feelings of tension thereafter.
Conclusion
The results of this study indicate that a daily ingestion of a
proprietary blend of 120 mg of NOPE and 105 mg of
EGCG can enhance compliance to a low caloric diet, total
mood score, feelings of fatigue, and confusion for 4-weeks,
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does not have any significant effects on weight loss,
changes in body composition, feelings of hunger, and
binge eating in a group of healthy, overweight adults. The
dose used in this study may have resulted in some degree
of habituation following 4-weeks of supplementation.
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